TSX: IGX
TSX: IGX
English English
en Englishfr French
Pharma Product
 
 
TECHNOLOGIES

IntelGenx’s Superior Film Technologies

 

INVESTOR PRESENTATION

View our latest presentation

 

DOWNLOAD
Development
 
 
Manufacturing

IntelGenx’s highly skilled team provides technological expertise in scale-up, technology transfer and manufacturing of pharmaceutical films.

 

INVESTOR PRESENTATION

View our latest presentation

 

DOWNLOAD
Partnering

 

 
 
Governance

 

 
 
Investors

 

 
 
 

VevaDermTM

 

VevaDerm Official logo

IntelGenx has a Long History in Transdermal Development & Manufacturing

 

 

Group 70

Leader in Pharmaceutical Films

Group 69

Fully integrated solution provider for Drug-In-Adhesive transdermal products

Group 67

Experience with many transdermal products, such as clonidine, estradiol, nitroclycerine and beta-blockers

 

 

Transdermal Technology Value Proposition

Addressing Chronic Diseases and Older Populations Needs
Growth in chronic disease prevalence and an increasing geriatric population are resulting in an increased need for transdermal medicines.

 

 

 Prolonged duration of action

  Group 76 

Reduced frequency of dosing 

 Reduced adverse effects

 

 

 

Transdermal Market Is an Attractive Niche
Driven by North American Segment with Revenue of US $3.2 billion

 

Global Transdermal Patch Revenue (Million USD) and Growth Rate (2014-2019)

Group 70

Market Share by Region (2019)

Group 69

Drug-In-Adhesive Patch
Versatile, Controlled and Predictable Drug Delivery System

 

Group 70

 

Group 77  Controlled & predictable drug delivery through the skin

Group 77  High loading drug capacity

Group 77  Single or multilayers design

Group 69

 

Backing Solvent-casted foil
Drug-in-adhesive Dispersed drug, polymers, plasticizers,
penetration enhancers, etc.
Release liner  Siliconized or fluoro-siliconized polyester film

Comprehensive
Service Portfolio

 

Group 70
R&D
  • Formulation
  • Permeability & Solubility Study
  • Analytical Method Development
Group 70
Clinical Trials
  • CTA & IND Applications
  • CRO Assistance
  • Trial Monitoring
  • Data Analysis
Group 70
IP
  • 70+ Patents & Applications
  • Patented Products & Technologies
  • Patent Filings
  • Freedom-to-operate Opinionst
Group 70
Operations
  • State-of-the-Art Manufacture
  • Full Scale Manufacturing
  • Finished Product Testing
  • Cost Effective
Group 70
Regulatory & Quality
  • Dossiers in Multiple Territories (EU, US)
  • Compliant to ICH, GMP & ISO
  • Health Canada Approved Mfg Site
 

Transdermal Development & Manufacturing
Integrated Offering

  • Significant formulation development experience focused on drug-inadhesive patches
  • Single and multilayer patch capabilities
  • Pilot scale equipment ready for solvent based transdermal patches and commercial coater installation by end of 2020

2
Ralph Yeung LAS8697 1
middle banner VersaFilm
 

State-of-the-Art
Film Manufacturing Facility

 

Ralph Yeung 8     Intelgenx Transdermal3    
17,000 sq ft facility in Montreal fully GMP compliant
Health Canada certified – Drug Establishment License (DEL) obtained in December 2017
Manufacturing highly scalable using
existing space
Committed to:

Reducing Costs
Accelerating Processes
Mitigating Risks
middle banner VersaFilm
 

Transdermal Delivery of Cannabinoids
Fast Track Development Program

  • IntelGenx has extensive experience developing & manufacturing THC & CBD drug products
  • Transdermal cannabinoid product presents many advantages
    • Ease of administration for flexible release of THC and CBD
    • Ability to decrease cannabinoid time-to-onset and increase duration of action
    • Continuous release of cannabinoids to allow for all-day effect
    • Discreet administration
  • Low competition and high margin for transdermal delivery

 

 

Experienced with Controlled Substances & Cannabis

 

Group 85 

IntelGenx holds:

  A Narcotics License
  A Precursor License
  A Cannabis License
 Group 85 We can export to the U.S.
• Possibility to export products containing controlled substances of Level 3 and below
• Export quantities of products containing controlled substances not limited by DEA imposed quota for Level 3 and below